Illumina, Inc. (BVMF:I1LM34)
Brazil · Delayed Price · Currency is BRL | Market Cap | 234.30B +182.4% |
| Revenue (ttm) | 23.21B +4.9% |
| Net Income | 4.26B -34.4% |
| EPS | 5.74 -32.1% |
| Shares Out | n/a |
| PE Ratio | 53.59 |
| Forward PE | 50.19 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 96 |
| Open | 298.12 |
| Previous Close | 298.12 |
| Day's Range | 298.12 - 311.83 |
| 52-Week Range | 115.95 - 311.83 |
| Beta | 1.42 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Oct 29, 2026 |
About Illumina
Illumina, Inc. provides sequencing- and array-based solutions for genetic and genomic analysis in the Americas, Europe, Greater China, the Asia Pacific, the Middle East, and Africa. The company offers sequencing- and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest. It also provides whole... [Read more]
News
Illumina To Webcast Upcoming Investor Conference
SAN DIEGO, Oct. 27, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced that members of its management team will participate at the following investor conference: Upcoming Investor Conf...
Moderna's Rally May Have Run Out of Steam. Here's What to Watch Next
Moderna's stock has taken a big hit that could signal the end of this year's cancer vaccine-driven rally. It may not be too late to play the forces behind its rise.
Illumina downgraded to Equal Weight from Overweight at Stephens
Stephens downgraded Illumina (ILMN) to Equal Weight from Overweight with a price target of $275, up from $213.
Stephens downgrades Illumina and 10x Genomics following outperformance
As previously reported, Stephens analyst Mason Carrico downgraded Illumina (ILMN) to Equal Weight from Overweight with a price target of $275, up from $213, and 10x Genomics (TXG) to Equal…
Edwards Lifesciences added to ‘Core Ideas’ list at Evercore, Illumina removed
Evercore ISI raised the firm’s price target on Edwards Lifesciences (EW) to $102 from $100 and keeps an Outperform rating on the shares, which were also added to the firm’s…
Illumina BioInsight Platform expands with new software to accelerate the path from sequencing to discovery
DRAGEN Ultra, BioInsight Platform Workflow Orchestrator, and BioInsight Platform Learning Cohorts are now available in early access, incorporating new AI-driven approaches to analysis, automation, and...
Illumina price target raised to $300 from $205 at Canaccord
Canaccord raised the firm’s price target on Illumina (ILMN) to $300 from $205 and keeps a Buy rating on the shares. The firm updated its model ahead of Q3 results.
Illumina launches BioInsight Platform, its first unified software environment to help accelerate genomic and multiomic breakthroughs
The new platform brings together advanced analysis, purpose-built AI, and curated biological data so researchers can move more quickly from complex genomic and multiomic data to actionable insight Inc...
Illumina sets up commercial paper program for up to $1.0B
On October 8, Illumina (ILMN) “entered into definitive documentation to establish an unsecured commercial paper program pursuant to which the Company may issue short-term, unsecured commercial paper n...
Illumina price target raised to $270 from $210 at TD Cowen
TD Cowen raised the firm’s price target on Illumina (ILMN) to $270 from $210 and keeps a Hold rating on the shares. The firm adjusted targets in the life science…
Illumina price target raised to $168 from $140 at BofA
BofA raised the firm’s price target on Illumina (ILMN) to $168 from $140 and keeps an Underperform rating on the shares. The life science tools sector has further re-rated since…
Illumina to Announce Third Quarter 2026 Financial Results on Thursday, October 29, 2026
SAN DIEGO, Oct. 8, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) announced today that it will issue results for the third quarter 2026 following the close of market on Thursday, October 29, 2026....
Illumina releases SpliceAI2 to help advance rare disease research
In a rare disease research dataset, SpliceAI2 identified 17% more disease-relevant variants compared to other splicing models Illumina's genomic AI models now collectively enable researchers to identi...
Illumina price target raised to $200 from $160 at Barclays
Barclays raised the firm’s price target on Illumina (ILMN) to $200 from $160 and keeps an Underweight rating on the shares. The firm adjusted targets in the life science and…
Illumina price target raised to $310 from $230 at RBC Capital
RBC Capital analyst Dan Leonard raised the firm’s price target on Illumina (ILMN) to $310 from $230 and keeps an Outperform rating on the shares. The firm notes that its…
Illumina price target raised to $305 from $226 at Guggenheim
Guggenheim analyst Subbu Nambi raised the firm’s price target on Illumina (ILMN) to $305 from $226 and keeps a Buy rating on the shares. The firm adjusted its models and…
The Top HealthTech Questions Landing on Our Desks
Strong performance across the healthtech sector over the past two quarters has sparked renewed market interest in medical innovation. Given the volume of inquiries landing on our desks, we compiled th...
Illumina price target raised to $300 from $220 at Leerink
Leerink raised the firm’s price target on Illumina (ILMN) to $300 from $220 and keeps an Outperform rating on the shares. The firm cites comparable sales and incremental growth from…
Illumina price target raised to $305 from $225 at Piper Sandler
Piper Sandler analyst David Westenberg raised the firm’s price target on Illumina (ILMN) to $305 from $225 and keeps an Overweight rating on the shares. Pharma and biotech spend roughly…
Illumina assumed with a Buy at UBS
UBS assumed coverage of Illumina (ILMN) with a Buy rating and $260 price target Illumina stands out as a compelling revenue reacceleration and margin-expansion opportunity, with high single digit grow...
Illumina Insider Sells $57M in Stock as ILMN Prepares to Join S&P 500
According to a recent SEC filing, Illumina ($ILMN) Director Keith Meister sold $57.19 million in company stock last week. However, the transaction does not necessarily signal a lack of confidence…
Prepare for These Three Stocks to Join the S&P 500 on September 21
On Friday evening, S&P Global ($SPGI) announced the latest additions and deletions to the S&P 500 (SPX). Effective Monday, September 21, Bloom Energy ($BE), Everpure ($P), and Illumina ($ILMN) will…
Bloom Energy, Illumina, and Everpure Set to Join S&P 500; Others to Join S&P 100, S&P MidCap 400, and S&P SmallCap 600
NEW YORK, Sept. 4, 2026 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P 500, S&P 100, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of tradi...
Bloom Energy and These 2 Stocks Are Joining the S&P 500
The S&P 500 is getting three new members this month, with Bloom Energy, Everpure, and Illumina joining the benchmark as part of its latest quarterly reshuffle.